| Author: | John W. Sweetenham, MD, Jame Abraham, MD, FACP | ISBN: | 9781617051319 |
| Publisher: | Springer Publishing Company | Publication: | November 2, 2012 |
| Imprint: | Demos Medical | Language: | English |
| Author: | John W. Sweetenham, MD, Jame Abraham, MD, FACP |
| ISBN: | 9781617051319 |
| Publisher: | Springer Publishing Company |
| Publication: | November 2, 2012 |
| Imprint: | Demos Medical |
| Language: | English |
Emerging Cancer Therapeutics is a trinary hard cover periodical that is designed to provide an up-to-date evidence-based review of a dedicated emerging cancer therapy topic of interest to clinicians and scientists involved in the care of patients receiving cancer treatment. It will serve as both a reference and instructional tool for students, housestaff, fellows, practicing clinical oncologists, radiation oncologists, surgical oncologists, cancer biologists, and interdisciplinary colleagues throughout the oncology spectrum.
With contributions from internationally recognized experts, Lymphomas combines chapters on the evolving role of established therapies such as stem cell transplantation with other disease-oriented chapters describing pathway-directed agents and the evolving paradigm of "personalized" lymphoma treatment. Coverage includes discussion of molecular characterization for different disease-specific lymphoma subtypes and the potential for developing "personalized" treatment as well as reviewing the evolving role of conventional chemotherapy, stem cell transplantation, and other salvage treatments. The articles examine a range of lymphoma subtypes, including Hodgkin lymphoma, T-cell lymphoma, aggressive B-cell lymphoma, and others.
Emerging Cancer Therapeutics is a trinary hard cover periodical that is designed to provide an up-to-date evidence-based review of a dedicated emerging cancer therapy topic of interest to clinicians and scientists involved in the care of patients receiving cancer treatment. It will serve as both a reference and instructional tool for students, housestaff, fellows, practicing clinical oncologists, radiation oncologists, surgical oncologists, cancer biologists, and interdisciplinary colleagues throughout the oncology spectrum.
With contributions from internationally recognized experts, Lymphomas combines chapters on the evolving role of established therapies such as stem cell transplantation with other disease-oriented chapters describing pathway-directed agents and the evolving paradigm of "personalized" lymphoma treatment. Coverage includes discussion of molecular characterization for different disease-specific lymphoma subtypes and the potential for developing "personalized" treatment as well as reviewing the evolving role of conventional chemotherapy, stem cell transplantation, and other salvage treatments. The articles examine a range of lymphoma subtypes, including Hodgkin lymphoma, T-cell lymphoma, aggressive B-cell lymphoma, and others.
